REFERENCES
1. WHO. Hepatitis B fact sheet. 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. [Last accessed 30 Dec 2025].
2. Feng Y, Fang L, Cao G. Epidemiological characteristics and precise prophylaxis and control of HBV-associated primary liver cancer. Hepatoma Res. 2025;11:5.
3. GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7:796-829.
4. Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023;20:524-37.
5. Chen Y, Lin J, Deng Y, et al. Association of human leukocyte antigen-DR-DQ-DP haplotypes with the risk of hepatitis B virus-related hepatocellular carcinoma. Hepatoma Res. 2022;8:8.
6. Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA integration: molecular mechanisms and clinical implications. Viruses. 2017;9:75.
7. Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018;319:1802-13.
8. Hirode G, Choi HSJ, Chen CH, et al.; RETRACT-B Study Group. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B Study). Gastroenterology. 2022;162:757-71.e4.
9. Yip TC, Wong GL, Chan HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2019;70:361-70.
10. Anderson RT, Choi HSJ, Lenz O, et al. Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19:463-72.
11. Le Bert N, Gill US, Hong M, et al. Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection. Gastroenterology. 2020;159:652-64.
12. Salimzadeh L, Le Bert N, Dutertre CA, et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest. 2018;128:4573-87.
13. Farag MS, van Campenhout MJH, Sonneveld MJ, et al. Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: multicentre randomized trial (PAS Study). J Viral Hepat. 2024;31:197-207.
14. Kusumoto S, Tanaka Y, Suzuki R, et al. Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma. J Hepatol. 2020;73:285-93.
15. Wu D, Kao JH, Piratvisuth T, et al. Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0. Clin Mol Hepatol. 2025;31:S134-64.
16. Yuen MF, Heo J, Jang JW, et al. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nat Med. 2021;27:1725-34.
17. Hou J, Zhang W, Xie Q, et al.; Piranga Study Group. Xalnesiran with or without an immunomodulator in chronic hepatitis B. N Engl J Med. 2024;391:2098-109.
19. Petersen J, Thompson AJ, Levrero M. Aiming for cure in HBV and HDV infection. J Hepatol. 2016;65:835-48.
20. Prescott NA, Biaco T, Mansisidor A, et al. A nucleosome switch primes hepatitis B virus infection. Cell. 2025;188:2111-26.e21.
22. Meier MA, Calabrese D, Suslov A, Terracciano LM, Heim MH, Wieland S. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load. J Hepatol. 2021;75:840-7.
23. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A. 2004;101:6669-74.
24. Lee BO, Tucker A, Frelin L, et al. Interaction of the hepatitis B core antigen and the innate immune system. J Immunol. 2009;182:6670-81.
25. Jiang M, Broering R, Trippler M, et al. Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen. J Viral Hepat. 2014;21:860-72.
26. Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development? J Hepatol. 2022;76:1249-62.
27. Li J, Liu S, Zang Q, Yang R, Zhao Y, He Y. Current trends and advances in antiviral therapy for chronic hepatitis B. Chin Med J. 2024;137:2821-32.
28. Gu F, Zeng K, Lan X, et al. Measuring HBV pregenomic RNA may be a potential biomarker to determine HBV functional cure in HIV/HBV-co-infected patients with HBsAg loss. J Med Virol. 2024;96:e29762.
29. Real CI, Lu M, Liu J, et al. Hepatitis B virus genome replication triggers Toll-like receptor 3-dependent interferon responses in the absence of hepatitis B surface antigen. Sci Rep. 2016;6:24865.
30. Xu Y, Hu Y, Shi B, et al. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol. 2009;46:2640-6.
31. Deng F, Xu G, Cheng Z, et al. Hepatitis B surface antigen suppresses the activation of nuclear factor kappa B pathway via interaction with the TAK1-TAB2 complex. Front Immunol. 2021;12:618196.
32. Zhang JW, Lai RM, Wang LF, et al. Varied immune responses of HBV-specific B cells in patients undergoing pegylated interferon-alpha treatment for chronic hepatitis B. J Hepatol. 2024;81:960-70.
33. Fang Z, Li J, Yu X, et al. Polarization of monocytic myeloid-derived suppressor cells by hepatitis B surface antigen is mediated via ERK/IL-6/STAT3 signaling feedback and restrains the activation of T cells in chronic hepatitis B virus infection. J Immunol. 2015;195:4873-83.
34. Qi R, Fu R, Lei X, et al. Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels. J Hepatol. 2024;80:714-29.
35. Thimme R, Bertoletti A, Iannacone M. Beyond exhaustion: the unique characteristics of CD8+ T cell dysfunction in chronic HBV infection. Nat Rev Immunol. 2024;24:775-6.
36. Xu H, Locarnini S, Wong D, et al. Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A. J Hepatol. 2022;76:34-45.
37. Huang D, Wu D, Wang P, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol. 2022;77:42-54.
38. Costa JP, de Carvalho A, Paiva A, Borges O. Insights into immune exhaustion in chronic hepatitis B: a review of checkpoint receptor expression. Pharmaceuticals. 2024;17:964.
39. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5:215-29.
40. Maini MK, Peppa D. NK cells: a double-edged sword in chronic hepatitis B virus infection. Front Immunol. 2013;4:57.
41. Fang Z, Zhang Y, Zhu Z, et al. Monocytic MDSCs homing to thymus contribute to age-related CD8+ T cell tolerance of HBV. J Exp Med. 2022;219:e20211838.
42. Tout I, Gomes M, Ainouze M, et al. Hepatitis B virus blocks the CRE/CREB complex and prevents TLR9 transcription and function in human B cells. J Immunol. 2018;201:2331-44.
43. Bénéchet AP, De Simone G, Di Lucia P, et al. Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. Nature. 2019;574:200-5.
44. Zhang Z, Zhang JY, Wang LF, Wang FS. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2012;27:223-30.
45. Fung S, Choi HSJ, Gehring A, Janssen HLA. Getting to HBV cure: the promising paths forward. Hepatology. 2022;76:233-50.
46. Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology. 2019;71:1070-92.
47. Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A. 2005;102:9913-7.
48. Belloni L, Allweiss L, Guerrieri F, et al. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012;122:529-37.
49. Gupta N, Goyal M, Wu CH, Wu GY. The molecular and structural basis of HBV-resistance to nucleos(t)ide analogs. J Clin Transl Hepatol. 2014;2:202-11.
50. De Clercq E, Holý A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov. 2005;4:928-40.
51. Lim J, Choi J. Optimize nucleot(s)ide analogues’ to prevent hepatocellular carcinoma in patients with chronic hepatitis B: a lesson from real-world evidence. Hepatoma Res. 2021;7:21.
52. Zheng S, Cao H, Zhang M, et al. A potent GalNAc-siRNA drug, RBD1016, leads to sustained HBsAg reduction and seroconversion in mouse models of HBV infection. Mol Ther Nucleic Acids. 2025;36:102627.
53. Fung S, Kwan P, Fabri M, et al. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: a 5-year randomised study. J Hepatol. 2017;66:11-8.
54. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886-93.
55. Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2011;9:274-6.
56. Jeng WJ, Chen YC, Chien RN, Sheen IS, Liaw YF. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2018;68:425-34.
57. Berg T, Simon KG, Mauss S, et al.; FINITE CHB study investigators [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B]. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. J Hepatol. 2017;67:918-24.
58. Gara N, Tana MM, Kattapuram M, et al. Prospective study of withdrawal of antiviral therapy in patients with chronic hepatitis B after prolonged virological response. Hepatol Commun. 2021;5:1888-900.
59. Liaw YF. Impact of therapy on the long-term outcome of chronic hepatitis B. Clin Liver Dis. 2013;17:413-23.
60. Lin CL, Kao JH. Prevention of hepatitis B virus-related hepatocellular carcinoma. Hepatoma Res. 2021;7:9.
61. Li S, Yang M, Ye L, et al. Real-world effectiveness of initial antiviral regimens in children with chronic hepatitis B: an age-stratified cohort study. EClinicalMedicine. 2025;88:103478.
62. Chen J, Li Y, Lai F, et al. Functional comparison of interferon-α subtypes reveals potent hepatitis B virus suppression by a concerted action of interferon-α and interferon-γ signaling. Hepatology. 2021;73:486-502.
63. Ye J, Chen J. Interferon and hepatitis B: current and future perspectives. Front Immunol. 2021;12:733364.
64. Zhang Y, Zhong X, Xi Z, Li Y, Xu H. Antiviral potential of the genus panax: an updated review on their effects and underlying mechanism of action. J Ginseng Res. 2023;47:183-92.
65. Xia Y, Stadler D, Lucifora J, et al. Interferon-γ and tumor necrosis factor-α produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology. 2016;150:194-205.
66. Cheng J, Zhao Q, Zhou Y, et al. Interferon alpha induces multiple cellular proteins that coordinately suppress hepadnaviral covalently closed circular DNA transcription. J Virol. 2020;94:e00442-20.
67. Karabay O, Tuna N, Esen S; PEG-HBV Study Group. Comparative efficacy of pegylated interferons α-2a and 2b in the treatment of HBeAg-negative chronic hepatitis B infection. Eur J Gastroenterol Hepatol. 2012;24:1296-301.
68. Wong GL. Updated Guidelines for the Prevention and Management of Chronic Hepatitis B-World Health Organization 2024 compared with China 2022 HBV Guidelines. J Viral Hepat. 2024;31 Suppl 2:13-22.
69. Lee SK, Kwon JH, Lee SW, et al. Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B. Liver Int. 2021;41:288-94.
70. Song A, Lin X, Lu J, et al. Pegylated interferon treatment for the effective clearance of hepatitis B surface antigen in inactive HBsAg carriers: a meta-analysis. Front Immunol. 2021;12:779347.
71. Wang J, Zhang Z, Zhu L, et al. Association of hepatitis B core antibody level and hepatitis B surface antigen clearance in HBeAg-negative patients with chronic hepatitis B. Virulence. 2024;15:2404965.
72. Brouwer WP, Xie Q, Sonneveld MJ, et al.; ARES Study Group. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study). Hepatology. 2015;61:1512-22.
73. Chi H, Hansen BE, Guo S, et al. Pegylated interferon Alfa-2b add-on treatment in hepatitis B virus envelope antigen-positive chronic hepatitis B patients treated with nucleos(t)ide analogue: a randomized, controlled trial (PEGON). J Infect Dis. 2017;215:1085-93.
74. Li J, Qu L, Sun X, et al. Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B naïve patients. J Viral Hepat. 2021;28:1381-91.
75. Hu C, Song Y, Tang C, et al. Effect of pegylated interferon plus tenofovir combination on higher hepatitis B surface antigen loss in treatment-naive patients with hepatitis B e antigen -positive chronic hepatitis B: a real-world experience. Clin Ther. 2021;43:572-81.e3.
76. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-98.
77. Lim SG, Yang WL, Ngu JH, et al. Switching to or add-on peginterferon in patients on nucleos(t)ide analogues for chronic hepatitis B: the SWAP RCT. Clin Gastroenterol Hepatol. 2022;20:e228-50.
78. Bourlière M, Rabiega P, Ganne-Carrie N, et al.; ANRS HB06 PEGAN Study Group. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. Lancet Gastroenterol Hepatol. 2017;2:177-88.
79. Matsumoto A, Nishiguchi S, Enomoto H, et al. Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B. J Gastroenterol. 2020;55:977-89.
80. Woo HY, Heo J, Tak WY, et al. Effect of switching from nucleos(t)ide maintenance therapy to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomized trial. PLoS One. 2022;17:e0270716.
81. Gill US, Kennedy PTF. Current therapeutic approaches for HBV infected patients. J Hepatol. 2017;67:412-4.
82. Marcellin P, Lau GK, Bonino F, et al.; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206-17.
83. Janssen HL, van Zonneveld M, Senturk H, et al.; HBV 99-01 Study Group, Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123-9.
84. Ahn SH, Marcellin P, Ma X, et al. Hepatitis B surface antigen loss with tenofovir disoproxil fumarate plus peginterferon Alfa-2a: week 120 analysis. Dig Dis Sci. 2018;63:3487-97.
85. Wang LJ, Li MW, Liu YN, et al. Natural history and disease progression of chronic hepatitis B virus infection. J Peking Univ. 2022;54:920-6.
86. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98.
87. Iannacone M, Beccaria CG, Allweiss L, et al. Targeting HBV with RNA interference: paths to cure. Sci Transl Med. 2025;17:eadv3678.
88. Hui RW, Mak LY, Seto WK, Yuen MF. RNA interference as a novel treatment strategy for chronic hepatitis B infection. Clin Mol Hepatol. 2022;28:408-24.
89. Wang CC, Kao JH. The role of hepatitis B surface antigen in nucleos(t)ide analogue cessation among Asian chronic hepatitis B patients: friend or foe? Hepatology. 2019;69:1843.
90. Gane E, Lim YS, Kim JB, et al. Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: results from randomized clinical trials. J Hepatol. 2023;79:924-32.
91. Gane EJ, Kim W, Lim TH, et al. First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection. J Hepatol. 2023;79:1139-49.
92. Thi EP, Ye X, Snead NM, et al. Control of hepatitis B virus with imdusiran, a small interfering RNA therapeutic. ACS Infect Dis. 2024;10:3640-9.
93. Yuen MF, Locarnini S, Lim TH, et al. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB. J Hepatol. 2022;77:1287-98.
94. Mak LY, Hui RW, Fung J, Seto WK, Yuen MF. Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress. Expert Opin Investig Drugs. 2023;32:971-83.
95. Yuen MF, Lim SG, Plesniak R, et al.; B-Clear Study Group. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl J Med. 2022;387:1957-68.
96. Yuen MF, Heo J, Kumada H, et al. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. J Hepatol. 2022;77:967-77.
97. Buti M, Heo J, Tanaka Y, et al. Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B. J Hepatol. 2025;82:222-34.
98. Yang L, Gong Y, Liu F, et al. A novel phthalazinone derivative as a capsid assembly modulator inhibits hepatitis B virus expression. Antiviral Res. 2024;221:105763.
99. Phillips S, Jagatia R, Chokshi S. Novel therapeutic strategies for chronic hepatitis B. Virulence. 2022;13:1111-32.
101. Sulkowski MS, Agarwal K, Ma X, et al. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection. J Hepatol. 2022;77:1265-75.
102. Asselah T, Chulanov V, Lampertico P, et al. Bulevirtide combined with pegylated interferon for chronic hepatitis D. N Engl J Med. 2024;391:133-43.
103. Suresh M, Li B, Huang X, et al. Agonistic activation of cytosolic DNA sensing receptors in woodchuck hepatocyte cultures and liver for inducing antiviral effects. Front Immunol. 2021;12:745802.
104. Rossi M, Vecchi A, Tiezzi C, et al. Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro. Gut. 2023;72:2123-37.
105. Wedemeyer H, Aleman S, Brunetto MR, et al.; MYR 301 Study Group. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med. 2023;389:22-32.
106. Bazinet M, Pântea V, Placinta G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon Alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy. Gastroenterology. 2020;158:2180-94.
107. Agarwal K, Ahn SH, Elkhashab M, et al. Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment. J Viral Hepat. 2018;25:1331-40.
108. Gane EJ, Dunbar PR, Brooks AE, et al. Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression. J Hepatol. 2023;78:513-23.
109. Gane E, Verdon DJ, Brooks AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study. J Hepatol. 2019;71:900-7.
110. Tak WY, Chuang WL, Chen CY, et al. Phase Ib/IIa randomized study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB. J Hepatol. 2024;81:949-59.
111. Wang G, Cui Y, Hu G, et al. HBsAg loss in chronic hepatitis B patients after 24-week treatment with subcutaneously administered PD-L1 antibody ASC22 (Envafolimab): interim results from a phase IIb extension cohort. Hepatology. 2023;78:abs5052. Available from: https://www.ascletis.com/data/upload/ueditor/20211119/5052-C%20Guiqiang%20@%20AASLD%202023%20LB%20Poster%20final.pdf. [Last accessed 30 Dec 2025].
112. Qian J, Xie Y, Mao Q, et al. A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic hepatitis B who are HBeAg-negative. Hepatology. 2025;81:1328-42.
113. Ma H, Lim TH, Leerapun A, et al. Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. JHEP Rep. 2021;3:100361.
114. Ma P, Jiang Y, Zhao G, et al. Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: a review. Eur J Cancer. 2024;209:114224.
115. Lugade AA, Bharali DJ, Pradhan V, Elkin G, Mousa SA, Thanavala Y. Single low-dose un-adjuvanted HBsAg nanoparticle vaccine elicits robust, durable immunity. Nanomedicine. 2013;9:923-34.
116. Ushach I, Zhu R, Rosler E, et al. Targeting TLR9 agonists to secondary lymphoid organs induces potent immune responses against HBV infection. Mol Ther Nucleic Acids. 2022;27:1103-15.
117. De Gregorio E, Caproni E, Ulmer JB. Vaccine adjuvants: mode of action. Front Immunol. 2013;4:214.
118. Aguilar JC, Lobaina Y, Muzio V, et al. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol. 2004;82:539-46.
119. Pan Y, Liu S, Zhao H, Yu Z, Qi Y, Huang Y. Multi-adjuvant emulsion system stabilized via mannosylated chitosan nanoparticles for subunit vaccine delivery. Int J Biol Macromol. 2025;310:143268.
120. Wusiman A, He J, Cai G, et al. Alhagi honey polysaccharides encapsulated into PLGA nanoparticle-based pickering emulsion as a novel adjuvant to induce strong and long-lasting immune responses. Int J Biol Macromol. 2022;202:130-40.
121. Li X, Liu Y, Yao H, et al. Safety, tolerability, and pharmacokinetics of the novel hepatitis B virus expression inhibitor GST-HG131 in healthy Chinese subjects: a first-in-human single- and multiple-dose escalation trial. Antimicrob Agents Chemother. 2022;66:e0009422.
122. Bazinet M, Pântea V, Cebotarescu V, et al. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2017;2:877-89.
123. Krebs K, Böttinger N, Huang LR, et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology. 2013;145:456-65.
124. Wong GLH, Yuen MF, Kennedy P, et al. LBP-020 Off-treatment antiviral efficacy and safety of repeat dosing of imdusiran followed by VTP-300 with or without nivolumab in virally-suppressed, non-cirrhotic subjects with chronic hepatitis B (CHB). J Hepatol. 2025;82:S79-80.
125. Yuen MF, Lim YS, Yoon KT, et al. VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study. Lancet Gastroenterol Hepatol. 2024;9:1121-32.
126. Wisskirchen K, Kah J, Malo A, et al. T cell receptor grafting allows virological control of Hepatitis B virus infection. J Clin Invest. 2019;129:2932-45.
127. Hui RW, Fung J, Seto WK, Yuen MF, Mak LY. Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies. Hepatol Int. 2025;19:704-19.
128. Hui RW, Mak LY, Fung J, Seto WK, Yuen MF. Prospect of emerging treatments for hepatitis B virus functional cure. Clin Mol Hepatol. 2025;31:S165-181.
129. Yuen MF, Asselah T, Jacobson IM, et al.; REEF-1 Study Group. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial. Lancet Gastroenterol Hepatol. 2023;8:790-802.
130. Wang D, Chen L, Li C, et al. CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy. J Nanobiotechnology. 2022;20:27.
131. Wu K, He M, Mao B, et al. Enhanced delivery of CRISPR/Cas9 system based on biomimetic nanoparticles for hepatitis B virus therapy. J Control Release. 2024;374:293-311.
132. Gorsuch CL, Nemec P, Yu M, et al. Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo. Mol Ther. 2022;30:2909-22.
133. Wang Y, Li Y, Zai W, et al. HBV covalently closed circular DNA minichromosomes in distinct epigenetic transcriptional states differ in their vulnerability to damage. Hepatology. 2022;75:1275-88.
134. Lampertico P, Brunetto MR, Craxì A, et al.; HERMES Study Group. Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D. J Viral Hepat. 2019;26:118-25.
135. Koffas A, Kumar M, Gill US, Jindal A, Kennedy PTF, Sarin SK. Chronic hepatitis B: the demise of the 'inactive carrier' phase. Hepatol Int. 2021;15:290-300.
136. Cao Z, Liu Y, Ma L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology. 2017;66:1058-66.
137. Wu F, Lu R, Liu Y, et al. Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers. Liver Int. 2021;41:2032-45.
138. Erken R, Loukachov VV, de Niet A, et al. A prospective five-year follow-up after peg-interferon plus nucleotide analogue treatment or no treatment in HBeAg negative chronic hepatitis B patients. J Clin Exp Hepatol. 2022;12:735-44.
139. Kim JH, Sinn DH, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology. 2017;66:335-43.
140. Wen WH, Chang MH, Zhao LL, et al. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol. 2013;59:24-30.
141. Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:466-76.
142. Zhang M, Li J, Xu Z, et al. Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B. Hepatol Int. 2024;18:435-48.
143. Liu Z, Lin C, Mao X, et al. Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people. Gut. 2023;72:2354-63.
144. Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389-98.
145. Wang MM, Wang GS, Shen F, Chen GY, Pan Q, Fan JG. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci. 2014;59:2571-9.
146. Huang SC, Su TH, Tseng TC, et al. Metabolic dysfunction-associated steatotic liver disease facilitates hepatitis B surface antigen seroclearance and seroconversion. Clin Gastroenterol Hepatol. 2024;22:581-90.e6.
147. Huang Y, Gan Q, Lai R, et al. Application of fatty liver inhibition of progression algorithm and steatosis, activity, and fibrosis score to assess the impact of non-alcoholic fatty liver on untreated chronic hepatitis B patients. Front Cell Infect Microbiol. 2021;11:733348.
148. Lee MH, Chen YT, Huang YH, et al. Chronic viral hepatitis B and C outweigh MASLD in the associated risk of cirrhosis and HCC. Clin Gastroenterol Hepatol. 2024;22:1275-85.e2.
149. Jin X, Chen YP, Yang YD, Li YM, Zheng L, Xu CQ. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One. 2012;7:e34198.
150. Chen K, Qu C. Impact of occult hepatitis B virus infection and high-fat diet on hepatocellular carcinoma development. Hepatoma Res. 2024;10:38.
151. Chen YC, Jeng WJ, Hsu CW, Lin CY. Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study. BMC Gastroenterol. 2020;20:146.
152. Matsushita K, Hoshino T. Novel diagnosis and therapy for hepatoma targeting HBV-related carcinogenesis through alternative splicing of FIR (PUF60)/FIRΔexon2. Hepatoma Res. 2018;4:61.
153. Lani L, Zaccherini G, Giannini EG, Trevisani F. Surveillance for patients at risk of hepatocellular carcinoma: how to improve its cost-effectiveness and expand the role of multidisciplinary tumor board? Hepatoma Res. 2025;11:9.
154. Jang JW, Kim JS, Kim HS, et al. Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Clin Mol Hepatol. 2021;27:207-18.
155. Mon HC, Lee PC, Hung YP, et al. Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy. J Hepatol. 2025;82:51-61.
156. Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med. 1991;324:1457-63.
157. Fu B, Ji Y, Hu S, et al. Efficacy and safety of anti-viral therapy for hepatitis B virus-associated glomerulonephritis: a meta-analysis. PLoS One. 2020;15:e0227532.
158. Peng MJ, Guo XQ, Zhang WL, et al. Effect of pegylated interferon-α2b add-on therapy on renal function in chronic hepatitis B patients: a real-world experience. Front Microbiol. 2022;13:980250.
159. Liu CJ, Chuang WL, Sheen IS, et al. Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV. Gastroenterology. 2018;154:989-97.
160. Cheng PN, Liu CJ, Chen CY, et al. Entecavir prevents HBV reactivation during direct acting antivirals for HCV/HBV dual infection: a randomized trial. Clin Gastroenterol Hepatol. 2022;20:2800-8.
161. Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut. 2021;70:1782-94.
162. Wang R, Guo H, Kou X, Chen R, Zhang R, Li J. The interaction effect between key autophagy-related biomarkers and HBV/HCV infections on the survival prognosis of hepatocellular carcinoma. Hepatoma Res. 2025;11:10.
163. Nevola R, Rinaldi L, Giordano M, Marrone A, Adinolfi LE. Mechanisms and clinical behavior of hepatocellular carcinoma in HBV and HCV infection and alcoholic and non-alcoholic fatty liver disease. Hepatoma Res. 2018;4:55.
164. Chang ML, Liaw YF. Emerging therapies for chronic hepatitis B and the potential for a functional cure. Drugs. 2023;83:367-88.
165. Cui F, Blach S, Manzengo Mingiedi C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023;8:332-42.
